MicroPort Scientific : Endovastec™ Receives Approval for Hercules™-LP Stent Graft System in India

New Delhi, India, 31 December 2021 - Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has recently received registration approval from the Indian Central Drugs Standard Control Organization (CDSCO) for its Hercules™ Low Profile Thoracic Stent Graft and Delivery System (Hercules™-LP) as the first Endovastec™ product to be approved for marketing in India. Hercules™-LP received CE marking in 2020 and currently is available in several overseas countries in South America and Asia.

Hercules™-LP is an upgrade to the Hercules™ thoracic stent graft system and is primarily indicated for the intervention of thoracic aortic aneurysms with a proximal/distal aneurysm neck length greater than 15 mm. The product is designed with a tip-capture mechanism, which results in a significant improvement in both accuracy and stability of stent positioning and release. It is one of the smallest in China in terms of the outer diameter of the delivery sheath, which has been reduced to 18 F for the first time, benefiting more patients. In addition, the PET soft inner sheath protects the stent system to easily cross the aortic arch. The multiple taper design of the stent ranging from 0-10mm can better conform the anatomical morphology of thoracic aortic dissection. Sloped stent readily conforming to the anatomy of the aorta enhances the overall flexibility.

According to reports, India, the second most populous country in the world, suffers from a high prevalence of hypertension and diabetes, which are the main causes of aortic disease. The approval of Hercules™-LP in India will benefit more local patients with its excellent performance, providing doctors and patients with a better solution for treating thoracic aortic disease and laying the foundation for the company to further develop overseas markets.